Previous Article | Next Article 
Infection and Immunity, November 2001, p. 6776-6784, Vol. 69, No. 11
0019-9567/01/$04.00+0 DOI: 10.1128/IAI.69.11.6776-6784.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
Biochemical and Biological Characterization of the
Protective Leishmania pifanoi Amastigote Antigen
P-8
M.
Colmenares,1
M.
Tiemeyer,2
P.
Kima,1,
and
D.
McMahon-Pratt1,*
Departments of Epidemiology and Public
Health1 and Cell
Biology,2 Yale University School of
Medicine, New Haven, Connecticut
Received 23 October 2000/Returned for modification 13 December
2000/Accepted 23 July 2001
 |
ABSTRACT |
The Leishmania pifanoi amastigote antigen P-8 has
been previously shown to induce protective immunity in a murine model
of cutaneous leishmaniasis (L. Soong, S. M. Duboise, P. Kima, and D. McMahon-Pratt, Infect. Immun. 63:3559-3566, 1995). As
this antigen is of interest for further vaccine studies, the
biochemical characterization of P-8 was undertaken. Sodium dodecyl
sulfate-polyacrylamide gel electrophoresis, Western-blot analysis, and
gel filtration chromatography revealed that P-8 antigen consisted of
two proteoglycolipid complexes. The P-8 epitope is associated with the
L. pifanoi amastigote-specific glycolipid components
found in the two complexes. The P-8 complex 1 (P-8c1) consists of a
56-kDa serine metalloproteinase, apolipoprotein E (derived from
fetal bovine serum), and amastigote-specific glycolipids. The P-8
complex 2 (P-8c2) consists of a 31-kDa cysteine proteinase associated
with amastigote glycolipids. Biochemical analyses suggest that the P-8
antigenic glycolipids may be distinct from previously described
Leishmania glycolipids
(glycosylinositolphospholipids and sphingoglycolipids).
Protective immunity studies revealed that P-8c1 (serine
metalloproteinase-glycolipid complex) confers comparable
protection against infection as immunopurified P-8. The isolated P-8c2
(cysteine proteinase-glycolipid complex) does not provide significant
protection, nor does stimulation with P-8c2 result in significant
T-cell activation in P-8- or P-8c2-vaccinated mice. Consequently, the
P-8c1 complex appears to be the immunodominant component of P-8.
 |
INTRODUCTION |
Protozoan parasites of the genus
Leishmania are associated with a broad spectrum of diseases,
ranging from simple cutaneous to visceral leishmaniasis.
Leishmania spp. are dimorphic obligate intracellular
parasites. Flagellated promastigotes replicate and differentiate in the
gut of the phlebotomine sandfly vector; transmission to humans or other
vertebrate hosts occurs when the sandfly takes a blood meal. In the
dermis, recently inoculated promastigotes are internalized by
phagocytic cells and undergo transformation into amastigotes.
Consequently, survival of the parasite within a mammalian host is
dependent on successful entry into a macrophage and transformation into
the nonmotile amastigote form. Amastigotes maintain the infection
within the vertebrate hosts, replicating in the parasitophorous vacuole
and eventually leading to the destruction of host cells and invasion of
new macrophages.
The observations that protective immunity against Leishmania
infection can be acquired in susceptible mice (23, 25, 34, 48-50) as well as in humans (2, 19, 37) have
indicated the possibility for the development of a vaccine against
leishmaniasis. In mice, studies of protection against cutaneous
leishmaniasis have been observed after immunization with
promastigote-derived molecules such as lipophosphoglycan, gp63, defined
gp63 epitopes, and gp46 (also known as M-2) (8, 20, 24,
32, 45, 49, 50, 58, 59). In the search for immunogens that
invoke potent host-protective responses, our group has been focused on
molecules that are preferentially expressed in the amastigote stage,
the primary form responsible for diseases in mammalian hosts; these studies have employed axenically cultured amastigotes of
Leishmania (5, 11, 13, 14, 39). Since the
curative response in naive infected animals requires a relatively long
time to develop, it is likely that the antigens responsible for
induction of self-healing in cutaneous leishmaniasis are synthesized by
amastigotes (44).
The efficacy of immunization of BALB/c mice with purified L. pifanoi amastigote proteins has been evaluated previously; three amastigote antigens (P-2 [also known as A-2], P-4, and P-8) were found to provide significant (but varying degrees of) protection against infection (52). Among these, immunization with the
amastigote external-membrane-associated antigen P-8 induced significant
and reproducible protection in BALB/c mice against infection with L. pifanoi and L. amazonensis (52).
L. amazonensis and L. pifanoi are members of the
L. mexicana complex and are the causative agents of both
cutaneous (limited) and diffuse cutaneous leishmaniasis (7,
18) in Central and South America. As an important factor for a
potential vaccine candidate, the protection provided by vaccination
with P-8 did not appear to be genetically restricted, as protection was
induced in mice with different H-2 haplotypes (BALB/c, CBA,
C57BL/6). As the P-8 antigen stimulates a predominately curative
Th1-like lymphocyte response in cutaneous leishmaniasis patients
infected with L. braziliensis (9), the
potential of this immunogen as human vaccine candidate appears feasible.
In this study we present the biochemical characterization of the P-8
antigen, as an initial step for defining the nature of immunodominant
epitopes of this vaccine candidate.
 |
MATERIALS AND METHODS |
Cell culture.
L. pifanoi MHOM/VE/60/Ltrod
amastigotes were cultured at 31°C in simplified F29 medium containing
20% heat-inactivated fetal bovine serum (FBS) (39).
Promastigote forms were derived from amastigotes by culture at 24°C
in Schneider's Drosophila medium (GIBCO) supplemented with
20% heat-inactivated FBS and gentamicin (10 µg/ml).
Antibodies.
The preparation and characterization of the
amastigote-specific monoclonal antibody (MAb) P-8 have been reported
previously (38). A polyclonal serum was obtained by
immunizing mice with the immunopurified antigen P-8, as described
below. The sheep polyclonal antibody Sp180 raised against L. chagasi promastigote gp63 was a gift from M. Wilson (University of
Iowa). Other antibodies and conjugates used were goat anti-human
apolipoprotein E (ApoE) polyclonal antibody (Chemicon, Temecula,
Calif.), anti-sheep immunoglobulin G (IgG) alkaline phosphatase
conjugate (Sigma), alkaline phosphatase-conjugated affiniPure
F(ab)2 fragment, rabbit anti-goat IgG, and goat
anti-mouse IgG (Jackson Research Laboratory, West Grove, Pa.).
Purification of the P-8 antigen.
The P-8 antigen was
purified as described previously (52), with the following
modifications. Surface membranes of washed L. pifanoi
amastigotes were isolated using nitrogen cavitation and differential
centrifugation. Membrane proteins were solubilized with 1%
decanoyl-N-methylglucamide (Mega-10; Sigma) at room
temperature for 2 h, at a protein/detergent ratio of 1:1. In order
to prevent aggregation, the mixture was centrifuged at 40,000 × g for 45 min at 4°C, and the supernatant was recovered and
incubated with 14.2 mM 2-mercaptoethanol (Sigma) at room temperature
for 30 min and subsequently alkylated by addition of iodoacetamide
(final concentration, 30 mM). The reduced and alkylated solubilized
membranes were fractionated by Sephadex G-25 (Pharmacia, Piscataway,
N.J.) gel exclusion chromatography to remove the excess of reagents. The sample was then diluted with phosphate-buffered saline (PBS) (137 mM NaCl, 2.7 mM KCl, 4.3 mM
Na2HPO4, 1.4 mM
KH2PO4, pH 7.4) and
subjected to P-8 immunoaffinity chromatography. After extensive washing
with PBS containing 0.01% Mega-10, P-8 antigen was eluted with elution
buffer (50 mM diethylamine, pH 11.5; 150 mM NaCl; 0.01% Mega-10) and
3-ml fractions were collected and immediately neutralized to pH 7 to 8 (using 1 M Tris-HCl, pH 5.3). The fractions eluted from the affinity
column were assessed for protein by measuring the absorbance at 280 and
320 nm; protein fractions were pooled, concentrated, and then stored at
20°C.
SDS-PAGE and immunoblot analyses.
Sodium dodecyl
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) was carried out
with a minigel system (Bio-Rad) and 12% acrylamide gels
(27). Samples were pretreated as indicated (reduced, nonreduced, heat-denatured, or nondenatured). Proteins were visualized by Coomassie brillant blue staining. For immunoblots, proteins were
transferred onto nitrocellulose membrane (Biotrace NT; Gelman Sciences), as described (56). Following transfer of
proteins to nitrocellulose and staining with Ponceau S (Sigma),
membranes were blocked for 1 h at room temperature in PBS
containing 5% nonfat dried milk (Carnation). The filters were then
incubated overnight at 4°C with the first antibody diluted, as
indicated, in PBS containing 1% nonfat milk, followed by incubation
with the appropriate alkaline phosphatase conjugate (1/5,000 dilution in PBS) for 2 h at room temperature. The reaction was detected with the substrate 5-bromo-4-chloro-3-indolyl-phosphate
(BCIP)-nitroblue tetrazolium (Kirkegaard & Perry Laboratories).
Detection of proteinase activity.
For the detection of
proteinase activity in polyacrylamide gels, SDS-PAGE was performed as
described above with the exceptions that the separating gel contained
0.5% gelatin (Bio-Rad) and samples were not heat denatured. Molecular
mass markers were consistently employed to determine the relative
migration of the proteinase activities within the gelatin-containing
gels. Electrophoresis was conducted at 4°C. After electrophoresis,
gels were washed for 30 min in acetate buffer, pH 5.3 (50 mM sodium
acetate, 200 mM NaCl, 1 mM EDTA), containing 0.1% Triton X-100 and
then washed twice (15 min) with the same buffer without detergent. For
inhibition studies, samples were incubated for 30 min at 4°C with the
inhibitor before electrophoresis, and then all the washing steps were
done in the presence of inhibitor. Buffer-equilibrated gels were
incubated overnight at 37°C in a humid chamber. The gels were then
stained with Coomassie brillant blue; protease activity was detected as a clear band on a blue-stained gelatin background.
Extraction and analysis of glycolipids.
Glycolipids were
extracted from either immunopurified P-8 or from total amastigote cells
by the glycolipid extraction procedure of Svennerholm and Fredman
(55). Briefly, starting material was homogenized on ice in
3 volumes of water and then 8 volumes of methanol was added. Following
rehomogenization, 4 volumes of chloroform was added and the extract was
rehomogenized again at room temperature. After overnight agitation,
enough water was added to bring the solvent ratio to 4:8:5.6
(chloroform-methanol-water), thereby inducing phase separation. The
resulting lower and upper phases were back extracted with upper and
lower phases previously prepared from pure solvent. All upper phases
and lower phases were combined separately and dried under a stream of nitrogen.
For subsequent analysis by high performance thin layer
chromatography (HPTLC), the dried lower phase was resuspended in
chloroform-methanol (1:2), and the dried upper phase was resuspended in
chloroform-methanol-water (4:8:3). After application to glass-backed
silica gel 60 HPTLC plates (Merck), glycolipid components were resolved
by developing in solvent A (chloroform-methanol-0.25% aqueous KCl,
60:35:8) or in solvent B (chloroform-methanol-1 N
NH4OH, 10:10:3).
Carbohydrate-containing bands were visualized by the orcinol
spray reagent (Sigma). Resolved components on HPTLC plates were probed
by immuno-overlay by the method of Magnani et al. (28). Briefly, after developing in solvent A or B, HPTLC plates were dried
and then immersed in 0.001% poly(isobutyl methacrylate) (Aldrich) in
hexane. Once freed of solvent by evaporation, the plates were blocked
for 20 min in 1% bovine serum albumin in PBS. Anti-P-8 antibody was
then placed on the plate at a 1:2 dilution in 0.1% bovine serum
albumin in PBS. Bound anti-P-8 antibody was detected by incubation with
peroxidase-conjugated anti-mouse IgG and followed by reaction with
diaminobenzidine-H2O2.
Carbohydrate analysis.
Portions of each glycolipid were
treated with hydrofluoric acid (HF) under conditions that selectively
remove phosphate esters (15). Specifically, between 1 and
10 nmol of purified glycolipid was dried in a plastic screw-top
Eppendorf tube and then chilled on ice. To each tube, 50 µl of cold
(
20°C) HF was added and the sample was briefly (2 to 3 s)
sonicated in a bath sonicator. Following incubation in a refrigerated
bath at 0°C, the samples were frozen on dry ice and the acid was
removed by lyophilization in a vacuum centrifuge. Hydrolysis was
empirically determined to be complete by 72 h (51).
Aliquots of 0.5 to 5 nmol of purified, HF-treated glycolipids were
dried in glass crimp-top microvials (Agilent Technologies), resuspended
in 100 µl of 2 M hydrochloric acid, and sealed. After 4 h at
100°C, the hydrolysates were quickly cooled on ice, decapped, and
evaporated to dryness in a vacuum centrifuge. After resuspension in
water, aliquots were injected onto a Dionex PA1 anion-exchange column
on a Dionex DX500 high-performance liquid chromatography (HPLC)
unit, equipped with PEAKNET software for resolution and
detection of neutral and amino sugars by high-pH anion-exchange
chromatography coupled to pulsed amperometric detection (Dionex AD20
detector) as described previously (21).
P-8 fractionation.
Immunopurified P-8 was fractionated by
gel filtration on a Sepharose CL-6B column. Total antigen (500 µg)
was applied to the column, and the different components were eluted
with PBS-0.01% Mega-10. Individual fractions were collected and
analyzed for proteinase activity using gelatin gels (as indicated
above) and by Western blotting with MAb P-8. The column was calibrated
with molecular mass standards (Bio-Rad), which included thyroglobulin (610 kDa), aldolase (158 kDa), ovalbumin (44 kDa), and myoglobin (17 kDa).
Immunization of mice and evaluation of infection.
Female
BALB/c mice (five per group; Jackson Laboratories, Bar Harbor, Maine)
were vaccinated with either 4 µg of whole immunopurified P-8 antigen
or 2 µg of P-8c1 (56-kDa serine-metalloproteinase-glycolipid complex)
or 2 µg of P-8c2 (31-kDa cysteine proteinase-glycolipid complex),
together with 100 µg of the adjuvant Corynebacterium parvum. Three injections were given at biweekly intervals. Mice receiving PBS (used to dilute the purified proteins) or 100 µg of
adjuvant alone served as controls. Before challenge, serum from the
mice was collected. Four weeks after the last immunization, mice were
challenged in the right hind foot with 105
stationary-phase L. pifanoi promastigotes. The course of
infection was monitored by measuring the increase in footpad thickness, compared with the uninfected footpad, with a dial gauge caliper, and
the result was expressed as a thickness ratio of the infected foot to
the noninfected foot.
Proliferation assays.
P8 reactive cells used in this study
were obtained from mice immunized with whole P8 in Freund's adjuvant
in the hind footpad 9 days prior or mice infected with L. pifanoi for up to 3 months. Lymph nodes were removed aseptically,
and a single-cell suspension was obtained. CD4+ T
cells were enriched by negative selection to more than 90% by panning
using MAbs to CD8, anti-major histocompatibility complex class II
(212.A1), and CD16 (also known as CD32). CD4+ T
lymphocytes (105/well) were then cultured in
96-well microtiter plates (Falcon) for 72 h in the presence of
fixed 5 × 104 RAW 264.7 cells/well
previously cultured with specific antigens as described previously
(26). Cultures were then pulsed with [3H]thymidine (0.5 µCi/well) and incubated
for 16 additional hours before harvesting. Stimulation indices were
calculated by dividing the total radioactivity incorporated in the
presence of antigen by the radioactivity incorporated in medium alone.
Amino acid sequencing.
For amino acid sequencing of the p34
component, immunopurified P-8 was separated using preparative SDS-12%
PAGE. The 34-kDa band or component was excised from the gel and was
then digested with trypsin. The resulting peptides were isolated using
HPLC and sequenced by the W. M. Keck Foundation, Biotechnology
Resource Laboratory (Yale University, New Haven, Conn.) according to
methods previously described (53).
PI-PLC digestion of glycolipids.
Digestion with
phosphatidylinositol (PI)-specific phospholipase C (PLC) (0.1 U/ml) was
performed in 20 mM Tris-acetate buffer, pH 7.5, containing 0.1% Triton
X-100 at 37°C for 60 min, as previously described (29).
 |
RESULTS |
Molecular complexity of immunopurified P-8 antigen.
When
immunopurified P-8 is analyzed by SDS-PAGE, consistently the
preparations primarily contain four major components (Fig. 1, lane 1), with estimated molecular
masses of 56, 43, 34, and 31 kDa. Although minor bands were observed,
these differed in individual preparations and may represent, in part,
degradation products. Interestingly, the immunoblot analysis of the
same sample revealed that only the 34- and 43-kDa bands are directly
recognized by the MAb used for the purification (Fig. 1, lane 2). When
immunopurified P-8 was analyzed by silver stain, these two bands
appeared to stain with a blue color rather than brown (data not shown),
indicative of lipid content. Further studies (detailed below) confirmed
this fact.

View larger version (42K):
[in this window]
[in a new window]
|
FIG. 1.
Analysis of immunopurified P-8. L.
pifanoi axenic amastigote membrane-associated antigen P-8 was
purified as indicated in Materials and Methods and then resolved by
SDS-12% PAGE under reducing conditions, followed by either Coomassie
blue staining (lane 1) or immunoblot analysis with MAb P-8 (lane 2).
|
|
The purified P-8 antigen was initially analyzed on
gelatin-copolymerized SDS-PAGE, under reducing and nonreducing
conditions. As shown in Fig. 2 (lane 3),
when 2-mercaptoethanol is added to the sample buffer, P-8 appears to
contain two components capable of gelatin digestion. These proteinases
have relative molecular masses of 56 and 31 kDa, respectively. Under
nonreducing conditions, only the 56-kDa band can be detected (Fig. 2,
lane 1).

View larger version (62K):
[in this window]
[in a new window]
|
FIG. 2.
Immunopurified P-8 gelatinase activity. Aliquots of
immunopurified P-8 were incubated with different inhibitors, without
preactivation (1,2) or after preactivation with 14 mM
2-mercaptoethanol (3, 4). For the serine proteinase, the
inhibitor tested was 1 mM phenylmethylsulfonyl fluoride
(2), and for the cysteine proteinase the inhibitor was 10 mM iodoacetamide (4). The enzymatic activities were
developed as indicated in Materials and Methods. Migration of molecular
mass markers (in kilodaltons) is indicated on the left.
|
|
To determine the identity of protein components associated with the 34- and 43-kDa bands present in the P-8 complex, the 34-kDa band was
excised from a preparative SDS-polyacrylamide gel, digested with
trypsin and the amino acid sequence was obtained from two tryptic
peptides isolated by HPLC. As shown in Table
1, both peptides have 100% homology with
the sequence of either mouse or rat ApoE. Peptide 56 had only a 50%
homology with the corresponding bovine sequence; however, this area of
sequence is known to reside in the hypervariable region of ApoE and
thus might not be generically representative of all cattle. It should
be noted that the Mr values for the
34- and 43-kDa antigenic components are consistent with those reported
for the migration of ApoE (22). Given the conditions employed for the isolation of the P-8 antigen (see Materials and Methods), it is unlikely that the ApoE found represents nonspecifically bound host protein. In addition, gel densitometric analyses indicate that the ratio of the 56-kDa to 43- plus 34-kDa bands is consistently 1 to 2.3 (±0.2) which would not be expected to occur in the case of adventitiously bound molecules. Further, the 34- and 43-kDa components are observed in Western blot analyses of tissue-derived amastigotes (38) as well as cultured organisms. These
results suggest that serum (host)-derived ApoE is a constituent of the P-8 antigen; however, further work is required to verify this point and
the cellular mechanisms involved in the incorporation of ApoE into the
P-8 antigen complex.
View this table:
[in this window]
[in a new window]
|
TABLE 1.
Comparison of amino acid sequences of two peptides from
the 34-kDa proteoglycolipid component of P-8 and ApoE
|
|
In order to investigate the potential glycolipid nature of the
components present in the 34- and 43-kDa bands, total glycolipids were
isolated from purified P-8, by extraction with
chloroform-methanol-water (4:8:3). HPTLC analysis with the solvent A of
the upper (aqueous)- and lower (organic and chloroform)-phase fractions
revealed the presence of four glycolipid species in immunopurified P-8
recognized by the MAb (Fig. 3). The
glycolipids P8-1, -2, and -3 partitioned only onto the lower phase and
are strongly recognized by MAb P-8; glycolipid P8-4 was detected in
both the aqueous and organic phases and had an apparently weaker
reaction with MAb P-8. These results clearly indicate that the P-8
epitope (recognized by the P-8 MAb) is associated with glycolipid
moieties and confirms the proteoglycolipid nature of the components
migrating at Mr 34,000 and
43,000. It should be noted that Western blot analyses clearly
indicate that the P-8 MAb does not recognize any component present in
FBS (migrating as ApoE, glycolipid or other
Mr constituent). Further, FBS
extracted for glycolipids, concentrated and analyzed by HPTLC
(as indicated above) does not possess components recognized by the P-8
MAb (data not shown). Consequently, the antigenic P-8 glycolipids
appear to be of parasite derivation.

View larger version (23K):
[in this window]
[in a new window]
|
FIG. 3.
HPTLC analysis of the glycolipid components in
immunopurified P-8. Glycolipids from immunopurified P-8 were isolated
as described in Materials and Methods, and the fractionated upper
(1) and lower (2) phases were analyzed by
HPTLC using solvent A and immunostained with MAb P-8. O and F mark the
origin and front of the TLC, respectively.
|
|
Immunopurified P-8 contains two independent protein-glycolipid
complexes.
Based upon the results (above) concerning the
biochemical composition and complexity of the P-8 antigen, two
possibilities were hypothesized concerning the P-8 complex. One
possibility is that the P-8 antigen is a large macromolecular complex
consisting of four glycolipids, two proteinases, and ApoE; this tight
complex can be dissociated by strong detergents (i.e., SDS) but not
under high-pH or reducing conditions (used in the isolation of the
antigen). The other possibility is that, independently, each protease
forms a distinct or stable complex with the glycolipid components
recognized by the P-8 MAb.
In order to determine the relation between the proteinases and the
glycolipids present in P-8, the immunopurified complex was fractionated
on a Sepharose CL-6B gel filtration column. Individual fractions were
analyzed for the presence of the 56-kDa proteinase and the 31-kDa
proteinase and also for reaction with MAb P-8 by Western blotting. As
shown in Fig. 4, the two proteinase
activities are recovered in different fractions; the 34- and 43-kDa
components containing the P-8 glycolipids, migrated with the 56-kDa
proteinase, forming a complex with a total molecular mass of >610 kDa.

View larger version (17K):
[in this window]
[in a new window]
|
FIG. 4.
Profile of P-8 fractionation by gel filtration
chromatography. Immunopurified P-8 was applied to a Sepharose CL-6B
column and eluted with PBS-0.01% Mega-10, and the various fractions
were analyzed by SDS-PAGE copolymerized with gelatin and by Western
blotting employing the MAb P-8, in order to detect the 56-kDa
serine-metalloproteinase, the 31-kDa cysteine proteinase, and the 43- and 34-kDa proteoglycolipids, respectively.
|
|
The fractions containing either the 31-kDa or the 56-kDa component were
pooled and the glycolipids were extracted and analyzed by HPTLC for
reaction with MAb P-8. The 56-kDa proteinase complex contains all the
glycolipid species detected in whole P-8 (P8-1 through P8-4), while the
31-kDa proteinase only contains the P8-3 component (data not shown).
These results indicate that purified P-8 is comprised of two
independent complexes: (i) a 56-kDa proteinase glycolipid complex
(P-8c1) and (ii) a 31-kDa proteinase associated with the
Leishmania amastigote glycolipid P8-3 (P-8c2).
Vaccine studies employing P-8c1 and P-8c2 proteoglycolipid
complexes.
The interest in the P-8 antigen comes from its
potential as a vaccine candidate against cutaneous leishmaniasis
(52). In order to determine the relative contribution of
the two P-8 complexes (P-8c1 and P-8c2) to the protection induced by
immunization with whole P-8, BALB/c mice (five per group) were
vaccinated with either the P-8c1 or P-8c2 complex (2 µg per
immunization per mouse) together with C. parvum as the
adjuvant. Control groups of mice either were immunized with whole
immunopurified unfractionated P-8 (4 µg per immunization per mouse;
positive control), or received C. parvum (adjuvant control)
or PBS alone. All mice were then challenged with
105 stationary-phase L. pifanoi
promastigotes, and the lesion size was measured at different times
postinfection. As indicated in Fig. 5,
the 56-kDa proteinase-glycolipid complex (P-8c1) confers comparable
protection to unfractionated P-8; the 31-kDa cysteine proteinase-glycolipid complex does not appear to contribute
significantly to protection against infection under these experimental
conditions.

View larger version (14K):
[in this window]
[in a new window]
|
FIG. 5.
Comparison of the immunoprotective properties of the two
complexes present in P-8. Immunopurified P-8 was fractionated by gel
filtration chromatography, the two P-8 complexes (P-8c1,
serine-metalloproteinase-glycolipid complex [ ]; P8-c2, cysteine
proteinase-glycolipid complex ( ) separated and used to immunize
mice. As controls, other mice were either nonimmunized (control, ),
immunized with the adjuvant (C. parvum) alone ( ) or
with whole P-8 and C. parvum (positive control, ).
After infection with L. pifanoi stationary-phase
promastigotes, the development of cutaneous lesions was monitored as
indicated in Materials and Methods. Error bars, standard
deviations.
|
|
Antigenic properties of P-8 components.
In order to determine
if the antigenicity of the individual complexes might contribute to the
overall protection observed, the immunologic properties of the 2 P-8
complexes were examined. The T-cell proliferative responses in
nonvaccinated BALB/c mice infected with L. amazonensis (Fig.
6A) as well as uninfected BALB/c mice
vaccinated with whole P-8 antigen (Fig. 6B) were determined. These
results indicate that the P-8c1 complex is preferentially recognized by
T cells derived from infected or vaccinated mice. Although there is a
defined T-cell response by mice vaccinated with whole P-8 antigen to
the P-8c2 cysteine proteinase complex, the stimulation indices (SI)
(SI, 4 to 6) found are significantly less than those found for the
P-8c1 serine proteinase complex (SI, 94 to 96). These results are
consistent with antibody data found for P-8, P-8c1, and/or P-8c2
immunized mice. While a strong antibody response was found for the
components of the P-8c1 complex, a negligible antibody response was
found for the P-8c2 complex (data not shown). These data suggest that
under the conditions employed for the vaccine studies, P-8c1 is the
dominant antigenic complex and consequently appears to be primarily
responsible for the protection observed.

View larger version (25K):
[in this window]
[in a new window]
|
FIG. 6.
Antigenic properties of P-8 components.
CD4+-P8 reactive T cells were obtained from mice infected
with L. pifanoi (3 months) (A) or mice immunized 9 days
previously with whole P8 in incomplete Freund's adjuvant (B), as
described in Materials and Methods. Stimulation indices were calculated
by dividing the total radioactivity incorporated in the presence of
antigen (whole immunopurified P-8, 5 µg; fractionated P-8c1, 5 µg;
fractionated P-8c2, 10 µg [a] or 5 µg [b]), by the
radioactivity incorporated in medium alone. Some values are indicated
in parentheses. Error bars, standard deviations.
|
|
Characterization of the glycolipid and proteinase components
present in the immunologically protective P-8c1 complex.
In order
to compare the glycolipids present in P-8c1 with previously described
L. mexicana GIPLs, total glycolipids from L. pifanoi amastigotes were extracted as described previously
(30, 31), partitioned in upper and lower phases, and
analyzed by HPTLC using solvent B and orcinol staining (Fig.
7). The glycolipids of L. pifanoi amastigotes recovered in the upper phase comigrate with
previously characterized L. mexicana promastigote GIPLs
(30), as determined by comparing the relative migration in
this solvent.

View larger version (61K):
[in this window]
[in a new window]
|
FIG. 7.
Characterization of the P-8 glycolipids. Total
glycolipids of L. pifanoi axenic amastigote were
extracted and partitioned into upper and lower phases. Glycolipids were
subjected to PI-PLC digestion and compared to untreated samples by
analysis on HPTLC using solvent B, and then detection with orcinol. The
relative migration of specific GIPL components is indicated in the
right margin. There is a clear loss of GIPL components upon PI-PLC
treatment but little or no change in the P-8 associated
glycolipids (P8-1 to P8-4). O and F mark the origin and front of the
TLC, respectively. Asterisk marks migration of impurities from the
enzyme preparation.
|
|
The susceptibility of the P-8 glycolipids to cleavage by PI-PLC was
also determined. As shown in Fig. 7, the amastigote GIPLs recovered in
the upper (aqueous) phase (iM3, iM4, EPiM3, and EPiM4) are sensitive to
PI-PLC. These results are consistent with those previously described
(31). The P8 species (P8-1, P8-2, P8-3, and P8-4), in
contrast, are resistant to PLC digestion under these conditions.
Therefore, these results suggest that the P-8 epitope is associated
with glycolipid components different from previously described
Leishmania GIPLs. In addition, preliminary results indicate that the purified bands corresponding to P8-1 to P8-4 consistently revealed the presence of mannose in all species. The carbohydrate composition of the various P-8 glycolipids was determined to be as
follows: P8-1, 1GalN:1Gal:2Man; P8-2, 1Gal:2Man; P8-3, 1Gal:1Man; P8-4,
1GalN:1Gal:1Man. The presence of mannose indicates that the P-8
glycolipids are distinct from previously described amastigote glycosphingolipids (GSL) (54). Further analyses are in
progress to determine the complete structure of these novel glycolipid components.
The 56-kDa proteinase present in P-8c1 can be detected on
gelatin-copolymerized SDS-PAGE under nonreducing conditions, and this
activity can be inhibited by the presence of the serine protease specific inhibitor phenylmethylsulfonyl fluoride (Fig. 2, lane 2) and
also the metalloproteinase inhibitor 1,10 phenanthroline (data not
shown). These results classify the 56-kDa band of P-8c1 as a
serine-metalloproteinase.
A major surface metalloproteinase of Leishmania promastigote
(gp63) has been described previously and extensively studied. We have
analyzed whether the 56-kDa serine-metalloproteinase present in P-8
might be the L. pifanoi axenic amastigote homologue of gp63.
As shown in Fig. 8, the polyclonal
antibody sp180 raised against gp63 recognized, by Western blotting, a
major 63-kDa band in total amastigote protein (lane 2) but failed to
detect any component present in immunopurified P-8 (lane 4). Moreover,
the 63-kDa band detected by sp180 in L. pifanoi amastigotes
was localized in the cytoplasmic fraction of the parasite (data not
shown), as described by other authors (16, 47), rather
than the membrane fraction used for P-8 antigen isolation. Another
difference is that gp63 has been reported to be resistant to serine
proteinase inhibitors (47). These biochemical and
immunologic results suggest that the p56 proteinase is not a gp63
homologue.

View larger version (46K):
[in this window]
[in a new window]
|
FIG. 8.
Comparison of P-8 56-kDa serine-metalloproteinase and
gp63. Total protein from L. pifanoi axenic amastigotes
(lanes 1 and 2) or immunopurified P-8 (lanes 3 and 4) were resolved by
SDS-12% PAGE, transferred to nitrocellulose, and immunostained with a
polyclonal antibody raised against gp63 (lanes 2 and 4) or with a
polyclonal serum against whole P-8 (lanes 1 and 3).
|
|
Consequently, the P-8c1 complex appears to represent a distinct
membrane-associated antigen of Leishmania amastigotes. The role(s) of the glycolipid and protein components in the induction of
protection against infection is of further interest.
 |
DISCUSSION |
The importance of the membrane-associated amastigote antigen P-8
comes from previous results, demonstrating that vaccination of mice
with P-8 induces significant and reproducible protection against
cutaneous leishmaniasis (52). In addition, Coutinho et al.
(9) have found that, in patients suffering from American cutaneous leishmaniasis, cells activated in response to the antigen P-8
have predominantly a Th1-like cytokine profile, which is considered characteristic of a beneficial or curative T cell response.
In the present work we have analyzed the biochemical nature of P-8, as
an initial step for defining immunodominant epitopes of this vaccine
candidate. We have found that P-8 does not correspond to a simple
antigen but instead consisted of two macromolecular complexes (P-8c1
and P-8c2), each containing several tightly bound components. P-8c1
contains a serine-metalloproteinase, host serum ApoE, and four
amastigote-specific glycolipids. P-8c2 contains a cysteine proteinase
and an amastigote glycolipid, P8-3. Even though the MAb used to purify
this antigen recognizes the glycolipids present, the other components
of immunopurified P-8 copurify due to an apparently tight association
with the glycolipids. The complexes maintained their association
throughout the purification procedure, which involves detergent
solubilization (Mega-10) and alkaline pH treatment; however, a strong
detergent such as SDS was capable of dissociating most complex components.
As indicated above, the initial interest in the characterization of the
P-8 antigen was due to its immunologic and protective properties, as
observed in human patients and vaccinated mice, respectively. As P-8
antigen can provide complete protection against cutaneous murine
leishmaniasis, it was of interest to determine if one or both of the
distinct P-8 complexes were critical to this protection. When mice were
immunized with each of the two isolated P-8 complexes (P-8c1 or P-8c2),
only mice vaccinated with the P-8c1 complex (containing the
serine-metalloproteinase and the P8-1, -2, and -4 glycolipids) were
protected against infection; no significant protection was induced by
vaccination with the P-8c2 complex. The level of protection induced
with vaccination with P-8c1 was comparable to that found for whole P-8.
These results are in agreement with the differences in the humoral and
cellular immune responses observed for the P-8c1 and P-8c2 complexes in infected or vaccinated mice.
The 31-kDa protein present in P-8c2 complex has been characterized as a
cysteine protease due to its activation by thiols and inhibition by
iodoacetamide. Abundant developmentally regulated cysteine proteinases
are characteristic of the intracellular amastigote form of L. pifanoi and other species of the L. mexicana complex (12, 17, 40, 41). These enzymes appear to be essential to
parasite growth (8, 17, 40) and have been proposed as potential chemotherapeutic targets. The cysteine proteases of L. mexicana complex described to date have been classified as cathepsin L-like or cathepsin B-like (4, 36, 42, 43). Without further molecular characterization, we cannot identify the P-8
31-kDa cysteine protease with a previously described enzyme. The
interesting characteristic of this enzyme is that it is primarily localized in amastigote surface membrane; further, in axenically cultured amastigotes, the enzyme appears to be expressed as an inactive
form, as it requires the presence of a thiol reagent for activation.
These results suggest an enzymatic role only upon entry of the
Leishmania amastigote into the parasitophorous milieu of the
macrophage, which is predominantly reducing (1).
The 56-kDa protein present in P-8c1 is a serine-metalloproteinase.
Serine proteases are members of one of the most biologically important
and widely distributed families of enzymes found throughout nature.
Members of this ubiquitous class of proteases are involved in a broad
range of biological processes and have also been implicated in
pathogenesis of a number of infectious diseases; parasite serine proteases may facilitate invasion of host tissue, metabolism of host
proteins and evasion of the host immune response (46). In
the case of Leishmania parasites, a serine oligopeptidase
from L. amazonensis promastigotes has been described
(10). This protease is localized in the cytoplasm and has
an apparent molecular mass of 101 kDa, differing from the 56-kDa serine
protease found in P-8c1. The Leishmania gp63
metalloproteinase is associated with both the promastigote and
amastigote stages. However, immunologic and enzymatic data clearly
indicate that the 56-kDa proteinase is distinct from the gp63
proteinase, which is primarily located within the megasomal compartment
of the amastigote and resistant to serine protease inhibitors
(16, 33, 47).
Glycosylphosphatidylinositol (GPI) glycolipids are major cell surface
constituents in Leishmania parasites, and distinct classes are present as membrane anchors for several surface glycoproteins, the
abundant lipophosphoglycan in promastigotes, and as a family of
low-molecular-weight GPI glycolipids (GIPLs). The surface expression of
both the lipophosphoglycan and GPI-anchored proteins is massively down-regulated in the intracellular amastigote stage of several species
(3, 33, 57). The GIPLs are major surface constituents on
both the promastigote and amastigote stages (29, 31, 57), while neutral GSL have been described as specific to the L. amazonensis amastigote (54). These GSL are ceramides
that contain galactose and glucose but not mannose and, hence, differ
from the P-8 glycolipids. The results presented here indicate that P-8
glycolipids also differ in their biochemical properties from previously
described L. mexicana amastigote GIPLs. However given the
general resistance of the P-8 glycolipids to digestion with PI-PLC, it
is possible that they are related to recently described
inositol-acylated GPI (glycolipids C and lyso-C') in Trypanosoma
brucei (35). The structural characterization of these
glycolipids is currently in progress and should clarify these points.
It will be of interest to further define the immunologic components
(glycolipid[s] and/or protein) of P-8c1 that are responsible for the
protection observed. In addition, given the surface localization of
this antigen, it will be of interest to further investigate the
potential biological role of the P-8 complexes in Leishmania amastigote attachment, internalization, and survival within the host
macrophage. This work is currently in progress.
 |
ACKNOWLEDGMENTS |
We thank Lynn Soong for helpful discussions and suggestions.
This work was supported by a grant from the National Institutes of
Health to D.M.-P. (AI27811).
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Yale University
School of Medicine, Department of Epidemiology and Public Health, P.O. Box 208034, 60 College St., New Haven, CT 06510-8034. Phone: (203) 785-4481. Fax: (203) 737-2921. E-mail:
diane.mcmahon-pratt{at}yale.edu.
Present address: Department of Microbiology and Cell Science,
University of Florida, Gainesville, FL 32611-0700.
Editor:
J. M. Mansfield
 |
REFERENCES |
| 1.
|
Antoine, J. C.,
E. Prina,
T. Lang, and N. Courret.
1998.
The biogenesis and properties of the parasitophorous vacuoles that harbour Leishmania in murine macrophages.
Trends Microbiol.
6:392-401[CrossRef][Medline].
|
| 2.
|
Antunes, C. M.,
W. Mayrink,
P. A. Magalhaes,
C. A. Costa,
M. N. Melo,
M. Dias,
M. S. Michalick,
P. Williams,
A. O. Lima,
J. B. Vieira, et al.
1986.
Controlled field trials of a vaccine against New World cutaneous leishmaniasis.
Int. J. Epidemiol.
15:572-580[Abstract/Free Full Text].
|
| 3.
|
Bahr, V.,
Y. D. Stierhof,
T. Ilg,
M. Demar,
M. Quinten, and P. Overath.
1993.
Expression of lipophosphoglycan, high-molecular weight phosphoglycan and glycoprotein 63 in promastigotes and amastigotes of Leishmania mexicana.
Mol. Biochem. Parasitol.
58:107-121[CrossRef][Medline].
|
| 4.
|
Bart, G.,
G. H. Coombs, and J. C. Mottram.
1995.
Isolation of lmcpc, a gene encoding a Leishmania mexicana cathepsin-B-like cysteine proteinase.
Mol. Biochem Parasitol.
73:271-274[CrossRef][Medline].
|
| 5.
|
Bates, P. A., and L. Tetley.
1993.
Leishmania mexicana: induction of metacyclogenesis by cultivation of promastigotes at acidic pH.
Exp. Parasitol.
76:412-423[CrossRef][Medline].
|
| 6.
|
Champsi, J., and D. McMahon-Pratt.
1988.
Membrane glycoprotein M-2 protects against Leishmania amazonensis infection.
Infect. Immun.
56:3272-3279[Abstract/Free Full Text].
|
| 7.
|
Convit, J., and F. Kerdel-Vegas.
1965.
Disseminated cutaneous leishmaniasis.
Arch. Dermatol.
91:439-445.
|
| 8.
|
Coombs, G. H., and J. Baxter.
1984.
Inhibition of Leishmania amastigote growth by antipain and leupeptin.
Ann. Trop. Med. Parasitol.
78:21-24[Medline].
|
| 9.
|
Coutinho, S. G.,
A. M. Da-Cruz,
A. L. Bertho,
M. A. Santiago, and P. De-Luca.
1998.
Immunologic patterns associated with cure in human American cutaneous leishmaniasis.
Braz. J. Med. Biol. Res.
31:139-142[Medline].
|
| 10.
|
de Andrade, A. S.,
M. M. Santoro,
M. N. de Melo, and M. Mares-Guia.
1998.
Leishmania (Leishmania) amazonensis: purification and enzymatic characterization of a soluble serine oligopeptidase from promastigotes.
Exp. Parasitol.
89:153-160[CrossRef][Medline].
|
| 11.
|
Doyle, P. S.,
J. C. Engel,
P. F. Pimenta,
P. P. da Silva, and D. M. Dwyer.
1991.
Leishmania donovani: long-term culture of axenic amastigotes at 37 degrees C.
Exp. Parasitol.
73:326-334[CrossRef][Medline].
|
| 12.
|
Duboise, S. M.,
M. A. Vannier-Santos,
D. Costa-Pinto,
L. Rivas,
A. A. Pan,
Y. Traub-Cseko,
W. De Souza, and D. McMahon-Pratt.
1994.
The biosynthesis, processing, and immunolocalization of Leishmania pifanoi amastigote cysteine proteinases.
Mol. Biochem. Parasitol.
68:119-132[CrossRef][Medline].
|
| 13.
|
Eperon, S., and D. McMahon-Pratt.
1989.
Extracellular amastigote-like forms of Leishmania panamensis and L. braziliensis. II. Stage- and species-specific monoclonal antibodies.
J. Protozool.
36:510-518[Medline].
|
| 14.
|
Eperon, S., and D. McMahon-Pratt.
1989.
Extracellular cultivation and morphological characterization of amastigote-like forms of Leishmania panamensis and L. braziliensis.
J. Protozool.
36:502-510[Medline].
|
| 15.
|
Fischer, W.,
I. Ishizuka,
H. R. Landgraf, and H. Herrmann.
1973.
Glycerophosphoryl diglucosyl diglyceride, a new phosphoglycolipid from Streptococci.
Biochim. Biophys. Acta
296:527-545[Medline].
|
| 16.
|
Frommel, T. O.,
L. L. Button,
Y. Fujikura, and W. R. McMaster.
1990.
The major surface glycoprotein (GP63) is present in both life stages of Leishmania.
Mol. Biochem. Parasitol.
38:25-32[CrossRef][Medline].
|
| 17.
|
Galvao-Quintao, L.,
S. C. Alfieri,
A. Ryter, and M. Rabinovitch.
1990.
Intracellular differentiation of Leishmania amazonensis promastigotes to amastigotes: presence of megasomes, cysteine proteinase activity and susceptibility to leucine-methyl ester.
Parasitology
101:7-13.
|
| 18.
|
Grimaldi, G., Jr., and R. B. Tesh.
1993.
Leishmaniases of the New World: current concepts and implications for future research.
Clin. Microbiol. Rev.
6:230-250[Abstract/Free Full Text].
|
| 19.
|
Gunders, A. E.,
L. Naggan, and D. Michaeli.
1972.
Follow-up study of a vaccination programme against cutaneous leishmaniasis. I. Vaccination with a 5 year-old human strain of L. tropica from the Negev.
Trans. R. Soc. Trop. Med. Hyg.
66:235-238[CrossRef][Medline].
|
| 20.
|
Handman, E., and G. F. Mitchell.
1985.
Immunization with Leishmania receptor for macrophages protects mice against cutaneous leishmaniasis.
Proc. Natl. Acad. Sci. USA
82:5910-5914[Abstract/Free Full Text].
|
| 21.
|
Hardy, M. R.,
R. R. Townsend, and Y. C. Lee.
1988.
Monosaccharide analysis of glycoconjugates by anion exchange chromatography with pulsed amperometric detection.
Anal. Biochem.
170:54-62[CrossRef][Medline].
|
| 22.
|
Horiuchi, K.,
S. Tajima,
M. Menju, and A. Yamamoto.
1989.
Structure and expression of mouse apolipoprotein E gene.
J. Biochem. (Tokyo)
106:98-103[Abstract/Free Full Text].
|
| 23.
|
Howard, J. G.,
S. Nicklin,
C. Hale, and F. Y. Liew.
1982.
Prophylactic immunization against experimental leishmaniasis: I. Protection induced in mice genetically vulnerable to fatal Leishmania tropica infection.
J. Immunol.
129:2206-2212[Medline].
|
| 24.
|
Jardim, A.,
J. Alexander,
H. S. Teh,
D. Ou, and R. W. Olafson.
1990.
Immunoprotective Leishmania major synthetic T cell epitopes.
J. Exp. Med.
172:645-648[Abstract/Free Full Text].
|
| 25.
|
Kahl, L. P.,
C. A. Scott,
R. Lelchuk,
G. Gregoriadis, and F. Y. Liew.
1989.
Vaccination against murine cutaneous leishmaniasis by using Leishmania major antigen/liposomes. Optimization and assessment of the requirement for intravenous immunization.
J. Immunol.
142:4441-4449[Abstract].
|
| 26.
|
Kima, P. E.,
L. Soong,
C. Chicharro,
N. H. Ruddle, and D. McMahon-Pratt.
1996.
Leishmania-infected macrophages sequester endogenously synthesized parasite antigens from presentation to CD4+ T cells.
Eur. J. Immunol.
26:3163-3169[Medline].
|
| 27.
|
Laemmli, U. K.
1970.
Cleavage of structural proteins during the assembly of the head of bacteriophage T4.
Nature
227:680-685[CrossRef][Medline].
|
| 28.
|
Magnani, J.,
D. F. Smith, and V. Ginsburg.
1980.
Detection of gangliosides that bind cholera toxin: direct binding of 125I-labeled toxin to thin-layer chromatograms.
Anal. Biochem.
109:399-402[CrossRef][Medline].
|
| 29.
|
McConville, M. J., and J. M. Blackwell.
1991.
Developmental changes in the glycosylated phosphatidylinositols of Leishmania donovani. Characterization of the promastigote and amastigote glycolipids.
J. Biol. Chem.
266:15170-15179[Abstract/Free Full Text].
|
| 30.
|
McConville, M. J.,
T. A. Collidge,
M. A. Ferguson, and P. Schneider.
1993.
The glycoinositol phospholipids of Leishmania mexicana promastigotes. Evidence for the presence of three distinct pathways of glycolipid biosynthesis.
J. Biol. Chem.
268:15595-15604[Abstract/Free Full Text].
|
| 31.
|
McConville, M. J., and M. A. Ferguson.
1993.
The structure, biosynthesis and function of glycosylated phosphatidylinositols in the parasitic protozoa and higher eukaryotes.
Biochem. J.
294:305-324.
|
| 32.
|
McMahon-Pratt, D.,
D. Rodriguez,
J. R. Rodriguez,
Y. Zhang,
K. Manson,
C. Bergman,
L. Rivas,
J. F. Rodriguez,
K. L. Lohman,
N. H. Ruddle, et al.
1993.
Recombinant vaccinia viruses expressing GP46/M-2 protect against Leishmania infection.
Infect. Immun.
61:3351-3359[Abstract/Free Full Text].
|
| 33.
|
Medina-Acosta, E.,
R. E. Karess,
H. Schwartz, and D. G. Russell.
1989.
The promastigote surface protease (gp63) of Leishmania is expressed but differentially processed and localized in the amastigote stage.
Mol. Biochem. Parasitol.
37:263-273[CrossRef][Medline].
|
| 34.
|
Mitchell, G. F.,
E. Handman, and T. W. Spithill.
1985.
Examination of variables in the vaccination of mice against cutaneous leishmaniasis using living avirulent cloned lines and killed promastigotes of Leishmania major.
Int. J. Parasitol.
15:677-684[CrossRef][Medline].
|
| 35.
|
Morita, Y. S.,
A. Acosta-Serrano,
L. U. Buxbaum, and P. T. Englund.
2000.
Glycosyl phosphatidylinositol myristoylation in African trypanosomes. New intermediates in the pathway for fatty acid remodeling.
J. Biol. Chem.
275:14147-14154[Abstract/Free Full Text].
|
| 36.
|
Mottram, J. C.,
M. J. Frame,
D. R. Brooks,
L. Tetley,
J. E. Hutchison,
A. E. Souza, and G. H. Coombs.
1997.
The multiple cpb cysteine proteinase genes of Leishmania mexicana encode isoenzymes that differ in their stage regulation and substrate preferences.
J. Biol. Chem.
272:14285-14293[Abstract/Free Full Text].
|
| 37.
|
Nascimento, E.,
W. Mayrink,
C. A. da Costa,
M. S. Michalick,
M. N. Melo,
G. C. Barros,
M. Dias,
C. M. Antunes,
M. S. Lima,
D. C. Taboada, et al.
1990.
Vaccination of humans against cutaneous leishmaniasis: cellular and humoral immune responses.
Infect. Immun.
58:2198-2203[Abstract/Free Full Text].
|
| 38.
|
Pan, A. A., and D. McMahon-Pratt.
1988.
Monoclonal antibodies specific for the amastigote stage of Leishmania pifanoi. I. Characterization of antigens associated with stage- and species-specific determinants.
J. Immunol.
140:2406-2414[Abstract].
|
| 39.
|
Pan, A. A.,
D. McMahon-Pratt, and B. M. Honigberg.
1984.
Leishmania mexicana pifanoi: antigenic characterization of promastigote and amastigote stages by solid phase radioimmunoassay.
J. Parasitol.
70:834-835[CrossRef][Medline].
|
| 40.
|
Pral, E. M.,
A. T. Bijovsky,
J. M. Balanco, and S. C. Alfieri.
1993.
Leishmania mexicana: proteinase activities and megasomes in axenically cultivated amastigote-like forms.
Exp. Parasitol.
77:62-73[CrossRef][Medline].
|
| 41.
|
Pupkis, M. F., and G. H. Coombs.
1984.
Purification and characterization of proteolytic enzymes of Leishmania mexicana mexicana amastigotes and promastigotes.
J. Gen. Microbiol.
130:2375-2383[Medline].
|
| 42.
|
Robertson, C. D., and G. H. Coombs.
1993.
Cathepsin B-like cysteine proteases of Leishmania mexicana.
Mol. Biochem. Parasitol.
62:271-279[CrossRef][Medline].
|
| 43.
|
Robertson, C. D., and G. H. Coombs.
1994.
Multiple high activity cysteine proteases of Leishmania mexicana are encoded by the Imcpb gene array.
Microbiology
140:417-424[Abstract].
|
| 44.
|
Russell, D. G.
1987.
Immunity to leishmaniasis: what properties delineate a protective antigen?
Ann. Inst. Pasteur Immunol.
138:774-781[Medline].
|
| 45.
|
Russell, D. G., and J. Alexander.
1988.
Effective immunization against cutaneous leishmaniasis with defined membrane antigens reconstituted into liposomes.
J. Immunol.
140:1274-1279[Abstract]. (Erratum, 140:2858.)
|
| 46.
|
Sakanari, J. A.,
C. E. Staunton,
A. E. Eakin,
C. S. Craik, and J. H. McKerrow.
1989.
Serine proteases from nematode and protozoan parasites: isolation of sequence homologs using generic molecular probes.
Proc. Natl. Acad. Sci. USA
86:4863-4867[Abstract/Free Full Text].
|
| 47.
|
Schneider, P.,
J. P. Rosat,
J. Bouvier,
J. Louis, and C. Bordier.
1992.
Leishmania major: differential regulation of the surface metalloprotease in amastigote and promastigote stages.
Exp. Parasitol.
75:196-206[CrossRef][Medline].
|
| 48.
|
Scott, P.,
E. Pearce,
S. Heath, and A. Sher.
1987.
Identification of T-cell-reactive antigens that protect BALB/c mice against Leishmania major.
Ann. Inst. Pasteur Immunol.
138:771-774[Medline].
|
| 49.
|
Scott, P.,
E. Pearce,
P. Natovitz, and A. Sher.
1987.
Vaccination against cutaneous leishmaniasis in a murine model. I. Induction of protective immunity with a soluble extract of promastigotes.
J. Immunol.
139:221-227[Abstract].
|
| 50.
|
Scott, P.,
E. Pearce,
P. Natovitz, and A. Sher.
1987.
Vaccination against cutaneous leishmaniasis in a murine model. II. Immunologic properties of protective and nonprotective subfractions of soluble promastigote extract.
J. Immunol.
139:3118-3125[Abstract].
|
| 51.
|
Seppo, A.,
M. Moreland,
H. Schweingruber, and M. Tiemeyer.
2000.
Zwitterionic and acidic glycosphingolipids of the Drosophila melanogaster embryo.
Eur. J. Biochem.
267:3549-3558[Medline].
|
| 52.
|
Soong, L.,
S. M. Duboise,
P. Kima, and D. McMahon-Pratt.
1995.
Leishmania pifanoi amastigote antigens protect mice against cutaneous leishmaniasis.
Infect. Immun.
63:3559-3566[Abstract].
|
| 53.
|
Stone, K. L., and K. R. Williams.
1993.
Enzymatic digestion of proteins and HPLC peptide isolation.
In
P. Matsudarra (ed.), A practical guide to protein and peptide purification for microsequencing, 2nd ed. Academic Press, New York, N.Y.
|
| 54.
|
Straus, A. H.,
S. B. Levery,
M. G. Jasiulionis,
M. E. Salyan,
S. J. Steele,
L. R. Travassos,
S. Hakomori, and H. K. Takahashi.
1993.
Stage-specific glycosphingolipids from amastigote forms of Leishmania (L.) amazonensis. Immunogenicity and role in parasite binding and invasion of macrophages.
J. Biol. Chem.
268:13723-13730[Abstract/Free Full Text].
|
| 55.
|
Svennerholm, L., and P. Fredman.
1980.
A procedure for the quantitative isolation of brain gangliosides.
Biochim. Biophys. Acta
617:97-109[Medline].
|
| 56.
|
Towbin, H.,
T. Staehelin, and J. Gordon.
1979.
Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications.
Proc. Natl. Acad. Sci. USA
76:4350-4354[Abstract/Free Full Text].
|
| 57.
|
Winter, G.,
M. Fuchs,
M. J. McConville,
Y. D. Stierhof, and P. Overath.
1994.
Surface antigens of Leishmania mexicana amastigotes: characterization of glycoinositol phospholipids and a macrophage-derived glycosphingolipid.
J. Cell Sci.
107:2471-2482[Abstract].
|
| 58.
|
Yang, D. M.,
N. Fairweather,
L. L. Button,
W. R. McMaster,
L. P. Kahl, and F. Y. Liew.
1990.
Oral Salmonella typhimurium (AroA-) vaccine expressing a major leishmanial surface protein (gp63) preferentially induces T helper 1 cells and protective immunity against leishmaniasis.
J. Immunol.
145:2281-2285[Abstract].
|
| 59.
|
Yang, D. M.,
M. V. Rogers, and F. Y. Liew.
1991.
Identification and characterization of host-protective T-cell epitopes of a major surface glycoprotein (gp63) from Leishmania major.
Immunology
72:3-9[Medline].
|
Infection and Immunity, November 2001, p. 6776-6784, Vol. 69, No. 11
0019-9567/01/$04.00+0 DOI: 10.1128/IAI.69.11.6776-6784.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Whitaker, S. M., Colmenares, M., Pestana, K. G., McMahon-Pratt, D.
(2008). Leishmania pifanoi Proteoglycolipid Complex P8 Induces Macrophage Cytokine Production through Toll-Like Receptor 4. Infect. Immun.
76: 2149-2156
[Abstract]
[Full Text]
-
Colmenares, M., Kima, P. E., Samoff, E., Soong, L., McMahon-Pratt, D.
(2003). Perforin and Gamma Interferon Are Critical CD8+ T-Cell-Mediated Responses in Vaccine-Induced Immunity against Leishmania amazonensis Infection. Infect. Immun.
71: 3172-3182
[Abstract]
[Full Text]